DelveInsight’s, “High-Grade Glioma Pipeline Insight 2024” report provides comprehensive insights about 150+ companies and 150+ pipeline drugs in High-Grade Glioma pipeline landscape. It covers the High-Grade Glioma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the High-Grade Glioma therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in High-Grade Glioma Research. Learn more about our innovative pipeline today! @ High-Grade Glioma Pipeline Outlook
Key Takeaways from the High-Grade Glioma Pipeline Report
- June 2024:- Eli Lilly and Company- A Randomized, Open-Label, Phase 2 Study Evaluating Abemaciclib in Combination With Temozolomide Compared to Temozolomide Monotherapy in Children and Young Adults With Newly Diagnosed High-Grade Glioma Following Radiotherapy. The purpose of this study is to measure the benefit of adding abemaciclib to the chemotherapy, temozolomide, for newly diagnosed high-grade glioma following radiotherapy.
- June 2024:- PhaseII Study of Ribociclib and Everolimus Following Radiotherapy in Pediatric and Young Adult Patients Newly Diagnosed With HGG Including DIPG, Which Harbor Alterations of the Cell Cycle and/or PI3K/mTOR Pathways. Nationwide Children's Hospital- The goal of this study is to determine the efficacy of the study drugs ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in pathways (cell cycle, PI3K/mTOR) that these drugs target.
- June 2024:- Plus Therapeutics- This is a multi-center, sequential cohort, open-label, volume and dose escalation study of the safety, tolerability, and distribution of 186RNL given by convection enhanced delivery to patients with recurrent or progressive malignant glioma after standard surgical, radiation, and/or chemotherapy treatment. The study uses a modified Fibonacci dose escalation, followed by an expansion at the maximum tolerated dose (MTD) to determine efficacy. The starting absorbed dose is 1mCi in a volume of 0.660mL.
- DelveInsight’s High-Grade Glioma pipeline report depicts a robust space with 150+ active players working to develop 150+ pipeline therapies for High-Grade Glioma treatment.
- The leading High-Grade Glioma Companies such as Mateon Therapeutics, BioMimetix, Oblato, Inc, PTC Therapeutics, Lee's Pharmaceutical Limited, Nuvation Bio, Inc., Laminar Pharmaceuticals, Basilea Pharmaceutica, Aadi, LLC, Erimos Pharmaceuticals, and others.
- Promising High-Grade Glioma Therapies such as BMX-001, Temozolomide, DB107-FC, ONC201, LAM561, PVSRIPO, Abemaciclib, and others.
Stay informed about the cutting-edge advancements in High-Grade Glioma Treatments. Download for updates and be a part of the revolution in cancer care @ High-Grade Glioma Clinical Trials Assessment
High-Grade Glioma Emerging Drugs Profile
- OT101: Mateon Therapeutics
OT101, a first-in-class RNA therapeutic, is designed to abrogate the immunosuppressive actions of TGF-beta 2. In a completed Phase II clinical study, OT-101 exhibited clinically meaningful single-agent activity and induced durable complete and partial responses in recurrent and refractory adult High-Grade Glioma patients, including adults with GBM. Further development of OT-101 may offer renewed hope for salvage therapy of pediatric DIPG patients who have this rare and fatal disease.
- BMX-001: BioMimetix
BMX-001 is being studied in a phase II randomized trial studying the safety and efficacy of the investigational drug in patients with newly diagnosed High-Grade Glioma patients who are being treated with brain radiation and temozolomide.
- OKN-007: Oblato, Inc.
OKN-007 is being developed by Oblato, Inc for the treatment of High-Grade Glioma. It is currently in phase I/II stage of development.
- PTC596: PTC Therapeutics
PTC596 is an orally active small molecule that targets tumor stem cell populations by reducing the function, activity and amount of BMI1. PTC596 acts by altering and destroying the BMI1 protein through a process called phosphorylation. PTC596 has potently inhibited BMI1 function in multiple tumor cell lines. In in vitro tests, PTC596 has preferentially targeted chemotherapy resistant cancer stem cells. Specifically, PTC596 preferentially depleted cancer stem cells in assays with tumor cell lines from fibrosarcoma, prostate and colon cancers. Conversely, the cytotoxic chemotherapies carboplatin, temozolomide, methotrexate and indibulin enriched the population of cancer stem cells in this assay. It is currently in phase I stage of development.
Learn more about High-Grade Glioma Drugs opportunities in our groundbreaking High-Grade Glioma Research and development projects @ High-Grade Glioma Unmet Needs
High-Grade Glioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravenous
- Oral
- Parenteral
- Subcutaneous
- Molecule Type
High-Grade Glioma Products have been categorized under various Molecule types such as
- Gene therapies
- Small molecule
- Vaccines
- Polymers
- Peptides
- Monoclonal antibodies
- Product Type
Discover the latest advancements in High-Grade Glioma Treatment by visiting our website. Stay informed about how we're transforming the future of disease @ High-Grade Glioma Market Drivers and Barriers, and Future Perspectives
Scope of the High-Grade Glioma Pipeline Report
- Coverage- Global
- High-Grade Glioma Companies- Mateon Therapeutics, BioMimetix, Oblato, Inc, PTC Therapeutics, Lee's Pharmaceutical Limited, Nuvation Bio, Inc., Laminar Pharmaceuticals, Basilea Pharmaceutica, Aadi, LLC, Erimos Pharmaceuticals, and others.
- High-Grade Glioma Therapies- BMX-001, Temozolomide, DB107-FC, ONC201, LAM561, PVSRIPO, Abemaciclib, and others.
- High-Grade Glioma Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- High-Grade Glioma Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
For a detailed overview of our latest research findings and future plans, read the full details of High-Grade Glioma Pipeline on our website @ High-Grade Glioma Drugs and Companies
Table of Content
- Introduction
- Executive Summary
- High-Grade Glioma: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- High-Grade Glioma – DelveInsight’s Analytical Perspective
- In-depth Commercial Assessment
- High-Grade Glioma Collaboration Deals
- Late Stage Products (Phase III)
- OT101: Mateon Therapeutics
- Mid Stage Products (Phase II and Phase I/II)
- BMX-001: BioMimetix
- OKN-007: Oblato, Inc.
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- PTC596: PTC Therapeutics
- Drug profiles in the detailed report…..
- Pre-clinical and Discovery Stage Products
- Drug Name: Company Name
- Inactive Products
- High-Grade Glioma Key Companies
- High-Grade Glioma Key Products
- High-Grade Glioma- Unmet Needs
- High-Grade Glioma- Market Drivers and Barriers
- High-Grade Glioma- Future Perspectives and Conclusion
- High-Grade Glioma Analyst Views
- High-Grade Glioma Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
